Human Psychopharmacology: Clinical and Experimental
July 10, 2007
Keith R. Laws, Joy Kokkalis
75 citations
Abstract A meta‐analysis was conducted to examine the impact of recreational ecstasy use on short‐term memory (STM), long‐term memory (LTM), verbal and visual memory. We located 26 studies containing memory data for ecstasy and non‐ecstasy users from which effect sizes could be derived. The analyses provided measures of STM and LTM in 610 and 439 ecstasy users and revealed moderate‐to‐large...
Journal of Forensic Sciences
July 2007
Teri L Martin, David A Chiasson, Stephen J. Kish
Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a psychoactive amphetamine derivative widely used for recreational purposes. Deaths caused by acute drug intoxication with MDMA are rare but can often involve a severe hyperthermic episode. The factors underlying the increased risk of some ecstasy users to a fatal drug reaction are not known. We present a case report of a 24-year-old woman...
Neurochemical Research
July 2007
María Miranda, Francisco Bosch-Morell, Siv Johnsen-Soriano et al.
The effects of MDMA administration on oxidative stress markers in rat eye and hippocampus, and the neuroprotective effects of the antioxidant 3,4-dihydro-6-hydroxy-7-methoxy-2,2-dimethyl-1(2H)-benzopyran (CR-6) have been studied. MDMA effects on liver were used for comparison with those in eye and hippocampus and to test CR-6 protective effects. Another goal was to test for apoptosis in retinal...
Psychopharmacology
July 2007
Clara Touriño, Rafaël Maldonado, Olga Valverde
3, 4-Methylenedioxymethamphetamine (MDMA) and cannabis are widely abused illicit drugs that are frequently consumed in combination. Interactions between these two drugs have been reported in several pharmacological responses observed in animals, such as body temperature, anxiety, cognition, and reward. However, the interaction between MDMA and cannabis in addictive processes such as physical...
Legal medicine (Tokyo, Japan)
July 2007
Małgorzata Kłys, Sebastian Rojek, Krzysztof Woźniak et al.
Drugs of abuse belonging to the amphetamine derivatives, which are often taken by adolescents and young adults, pose a serious risk associated with uncontrolled ingestion that sometimes leads to fatal outcomes. The number of deaths, however, related to Ecstasy is small when compared to the frequency of its use. The report presents a fatal poisoning with MDMA--Ecstasy of a 22-year-old male with...
Psychopharmacology
July 2007
Sami Ben Hamida, Erin Plute, Sonia Bach et al.
In our previous work, we showed that ethanol (EtOH) potentiates 3,4-methylenedioxymethamphetamine (MDMA)-induced hyperlocomotion while protecting against its hyperthermic effects. Whereas the effect on activity were found on all days (although declining over the three first days), the protection against hyperthermia completely disappeared on the second day. The latter effect was previously...
Neurotoxicology
July 2007
João Paulo Capela, Eduarda Fernandes, Fernando Remião et al.
3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy") is a psychoactive and hallucinogenic drug of abuse. MDMA has been shown to produce neurotoxicity both in animals and humans. MDMA and other amphetamines induce serotonergic and dopaminergic terminal neurotoxicity and also neurodegeneration in areas including the cortex, hippocampus, striatum and thalamus. Herein, we investigated the...
European Journal of Neuroscience
July 1, 2007
Sameera Dasari, Kert Viele, Amy Turner et al.
40 citations
Abstract The effects of para‐chlorophenylalanine (PCPA) and 3,4 methylenedioxy‐methamphetamine (MDMA, ‘ecstasy’) were investigated in relation to development, behavior and physiology in larval Drosophila . PCPA blocks the synthesis of serotonin (5‐HT) and MDMA is known to deplete 5‐HT in mammalian neurons; thus these studies were conducted primarily to target the serotonergic system. Treatment...
Psychiatry Research
June 18, 2007
Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users.
Neuroscience
June 8, 2007
J P Capela, Carla Macedo, P S Branco et al.
3,4-Methylenedioxymethamphetamine (MDMA or "ecstasy"), is a widely abused, psychoactive recreational drug that is known to induce neurotoxic effects. Human and rat hepatic metabolism of MDMA involves N-demethylation to 3,4-methylenedioxyamphetamine (MDA), which is also a drug of abuse. MDMA and MDA are O-demethylenated to N-methyl-alpha-methyldopamine (N-Me-alpha-MeDA) and alpha-methyldopamine...
British Journal of Pharmacology
May 29, 2007
E M Mills, K L Weaver, E Abramson et al.
Background and purpose: Studies were designed to examine the effects of dietary fats on metabolic effects of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy). These effects included hyperthermia, expression of uncoupling protein (UCP1 and 3) in brown adipose tissue or skeletal muscle and plasma free fatty acid (FFA) levels. Experimental approach: Male Sprague-Dawley rats were fed either a...
Addiction
May 22, 2007
Roberta Pacifici, Piergiorgio Zuccaro, Magı́ Farré et al.
39 citations
ABSTRACT Aims Cell‐mediated immune function and the occurrence of mild infectious diseases was investigated. Participants Polydrug consumers of 3,4‐methylenedioxymethamphetamine (MDMA) and cannabis ( n = 37) compared to cannabis users only ( n = 23) and control group ( n = 34). Design A longitudinal prospective study with three cross‐sectional evaluations at time 0 and at 6 months and 1 year...
European Journal of Pharmacology
May 21, 2007
Beatriz Goñi-allo, Elena Puerta, Isabel Hervias et al.
13 citations
Amiloride and several of its congeners known to block the Na(+)/Ca(2+) and/or Na(+)/H(+) antiporters potentiate methamphetamine-induced neurotoxicity without altering methamphetamine-induced hyperthermia. We now examine whether amiloride also exacerbates 3,4-methylenedioxymethamphetamine (MDMA)-induced long-term serotonin (5-HT) loss in rats. Amiloride (2.5 mg/kg, every 2 h x 3, i.p.) given at...
Journal of Analytical Toxicology
May 1, 2007
Luigino G. Apollonio, Ian R. Whittall, Dennis J. Pianca et al.
51 citations
The aim of this study was to evaluate the Bio-Quant Direct ELISA assays for amphetamine and methamphetamine in the routine presumptive screening of biological fluids. Standard concentration curves of the target analytes were assayed to assess sensitivity, and known concentrations of common amphetamine-type substances (ephedrine, pseudoephedrine, phentermine), designer analogues (MDA, MDMA,...
Synapse
April 5, 2007
Paul Cumming, Mette Møller, Kjeld Benda et al.
28 citations
Abstract The psychostimulant 3,4‐methylendioxymethamphetamine (MDMA, “ecstasy”) evokes degeneration of telencephalic serotonin innervations in rodents, nonhuman primates, and human recreational drug users. However, there has been no alternative to nonhuman primates for studies of the cognitive and neurochemical consequences of serotonin depletion in a large‐bodied animal. Therefore, we used...
Psychopharmacology
April 1, 2007
A C Parrott
85 citations
AIMS AND RATIONALE: The purpose of this study was to review whether methylenedioxymethamphetamine (MDMA) has the appropriate pharmacodynamic profile to be a therapeutic agent. Empirical descriptions of MDMA's subjective effects in humans will be reviewed to evaluate the proposal that MDMA has psychotherapeutic properties. The focus will be published evidence on its functional effects in...
Drug and Alcohol Dependence
March 16, 2007
Krista Lisdahl Medina, Paula K Shear
Given ecstasy's (MDMA) potential serotonergic neurotoxicity, it is plausible that regular ecstasy users would have an elevated prevalence of behavioral executive dysfunction or mood symptoms. However, recent studies have found that the relationship between ecstasy use and psychological symptoms was no longer significant after controlling for marijuana use (e.g., Morgan et al., 2002). The goal...
Depression and Anxiety
March 7, 2007
Heather Durdle, Leslie H. Lundahl, Chris‐ellyn Johanson et al.
34 citations
Previous research has suggested that 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) users have elevated depressive symptomatology, although it is not clear whether this is due to MDMA or other drug use. This study aimed to investigate the contributions of MDMA and cannabis use to Major Depressive Disorder in MDMA users. A total of 226 MDMA users were studied. Participants (65% male) reported...
Handbook of Contemporary Neuropharmacology
March 2, 2007
María Isabel Colado, Esther O'Shea, Alfred Richard Green
AbstractThe use of the club drugs 3, 4‐methylenedioxymethamphetamine (MDMA, “ecstasy”), gamma‐hydroxybutyrate (GHB), flunitrazepam (Rohypnol), ketamine and LSD is a popular practice among young people especially during all‐night dance parties or “raves“ due to their ability to enhance social experiences and/or alter perception. These substances belong to different classes of drugs: MDMA is an...
Pharmacology, Biochemistry, and Behavior
March 2007
Richard A Glennon, Richard Young, Małgorzata Dukat et al.
N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (methylenedioxymethamphetamine, MDMA, Ecstasy) and its structurally abbreviated congener N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA) are chemically related designer drugs, and PMMA is sometimes sold on the clandestine market as a substitute for MDMA. Prior drug discrimination studies have found that MDMA...